Report cover image

Topical Drugs CDMO Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 118 Pages
SKU # APRC20352383

Description

Summary

According to APO Research, The global Topical Drugs CDMO market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Topical Drugs CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Topical Drugs CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Topical Drugs CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Topical Drugs CDMO include Piramal Pharma Solutions, Pierre Fabre Group, PCI Pharma Services, MedPharm Ltd., Lubrizol Life Science, DPT Laboratories LTD., Contract Pharmaceuticals Limited, Cambrex Corporation and Bora Pharmaceutical CDMO and etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Topical Drugs CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Topical Drugs CDMO.
The Topical Drugs CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Topical Drugs CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Topical Drugs CDMO Segment by Company

Piramal Pharma Solutions
Pierre Fabre Group
PCI Pharma Services
MedPharm Ltd.
Lubrizol Life Science
DPT Laboratories LTD.
Contract Pharmaceuticals Limited
Cambrex Corporation
Bora Pharmaceutical CDMO
Ascendia Pharmaceuticals
Topical Drugs CDMO Segment by Type

Contract Development
Contract Manufacturing
Topical Drugs CDMO Segment by Application

Semi-Solid Formulations
Solid Formulations
Liquid Formulations
Others
Topical Drugs CDMO Segment by Application

Semi-Solid Formulations
Solid Formulations
Liquid Formulations
Others
Topical Drugs CDMO Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Topical Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Topical Drugs CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

118 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Topical Drugs CDMO by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Contract Development
2.2.3 Contract Manufacturing
2.3 Topical Drugs CDMO by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Semi-Solid Formulations
2.3.3 Solid Formulations
2.3.4 Liquid Formulations
2.3.5 Others
2.4 Assumptions and Limitations
3 Topical Drugs CDMO Breakdown Data by Type
3.1 Global Topical Drugs CDMO Historic Market Size by Type (2020-2025)
3.2 Global Topical Drugs CDMO Forecasted Market Size by Type (2026-2031)
4 Topical Drugs CDMO Breakdown Data by Application
4.1 Global Topical Drugs CDMO Historic Market Size by Application (2020-2025)
4.2 Global Topical Drugs CDMO Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Topical Drugs CDMO Market Perspective (2020-2031)
5.2 Global Topical Drugs CDMO Growth Trends by Region
5.2.1 Global Topical Drugs CDMO Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Topical Drugs CDMO Historic Market Size by Region (2020-2025)
5.2.3 Topical Drugs CDMO Forecasted Market Size by Region (2026-2031)
5.3 Topical Drugs CDMO Market Dynamics
5.3.1 Topical Drugs CDMO Industry Trends
5.3.2 Topical Drugs CDMO Market Drivers
5.3.3 Topical Drugs CDMO Market Challenges
5.3.4 Topical Drugs CDMO Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Topical Drugs CDMO Players by Revenue
6.1.1 Global Top Topical Drugs CDMO Players by Revenue (2020-2025)
6.1.2 Global Topical Drugs CDMO Revenue Market Share by Players (2020-2025)
6.2 Global Topical Drugs CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Topical Drugs CDMO Head Office and Area Served
6.4 Global Topical Drugs CDMO Players, Product Type & Application
6.5 Global Topical Drugs CDMO Manufacturers Established Date
6.6 Global Topical Drugs CDMO Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Topical Drugs CDMO Market Size (2020-2031)
7.2 North America Topical Drugs CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Topical Drugs CDMO Market Size by Country (2020-2025)
7.4 North America Topical Drugs CDMO Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Topical Drugs CDMO Market Size (2020-2031)
8.2 Europe Topical Drugs CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Topical Drugs CDMO Market Size by Country (2020-2025)
8.4 Europe Topical Drugs CDMO Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Topical Drugs CDMO Market Size (2020-2031)
9.2 Asia-Pacific Topical Drugs CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Topical Drugs CDMO Market Size by Country (2020-2025)
9.4 Asia-Pacific Topical Drugs CDMO Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Topical Drugs CDMO Market Size (2020-2031)
10.2 South America Topical Drugs CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Topical Drugs CDMO Market Size by Country (2020-2025)
10.4 South America Topical Drugs CDMO Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Topical Drugs CDMO Market Size (2020-2031)
11.2 Middle East & Africa Topical Drugs CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Topical Drugs CDMO Market Size by Country (2020-2025)
11.4 Middle East & Africa Topical Drugs CDMO Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Piramal Pharma Solutions
12.1.1 Piramal Pharma Solutions Company Information
12.1.2 Piramal Pharma Solutions Business Overview
12.1.3 Piramal Pharma Solutions Revenue in Topical Drugs CDMO Business (2020-2025)
12.1.4 Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio
12.1.5 Piramal Pharma Solutions Recent Developments
12.2 Pierre Fabre Group
12.2.1 Pierre Fabre Group Company Information
12.2.2 Pierre Fabre Group Business Overview
12.2.3 Pierre Fabre Group Revenue in Topical Drugs CDMO Business (2020-2025)
12.2.4 Pierre Fabre Group Topical Drugs CDMO Product Portfolio
12.2.5 Pierre Fabre Group Recent Developments
12.3 PCI Pharma Services
12.3.1 PCI Pharma Services Company Information
12.3.2 PCI Pharma Services Business Overview
12.3.3 PCI Pharma Services Revenue in Topical Drugs CDMO Business (2020-2025)
12.3.4 PCI Pharma Services Topical Drugs CDMO Product Portfolio
12.3.5 PCI Pharma Services Recent Developments
12.4 MedPharm Ltd.
12.4.1 MedPharm Ltd. Company Information
12.4.2 MedPharm Ltd. Business Overview
12.4.3 MedPharm Ltd. Revenue in Topical Drugs CDMO Business (2020-2025)
12.4.4 MedPharm Ltd. Topical Drugs CDMO Product Portfolio
12.4.5 MedPharm Ltd. Recent Developments
12.5 Lubrizol Life Science
12.5.1 Lubrizol Life Science Company Information
12.5.2 Lubrizol Life Science Business Overview
12.5.3 Lubrizol Life Science Revenue in Topical Drugs CDMO Business (2020-2025)
12.5.4 Lubrizol Life Science Topical Drugs CDMO Product Portfolio
12.5.5 Lubrizol Life Science Recent Developments
12.6 DPT Laboratories LTD.
12.6.1 DPT Laboratories LTD. Company Information
12.6.2 DPT Laboratories LTD. Business Overview
12.6.3 DPT Laboratories LTD. Revenue in Topical Drugs CDMO Business (2020-2025)
12.6.4 DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio
12.6.5 DPT Laboratories LTD. Recent Developments
12.7 Contract Pharmaceuticals Limited
12.7.1 Contract Pharmaceuticals Limited Company Information
12.7.2 Contract Pharmaceuticals Limited Business Overview
12.7.3 Contract Pharmaceuticals Limited Revenue in Topical Drugs CDMO Business (2020-2025)
12.7.4 Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio
12.7.5 Contract Pharmaceuticals Limited Recent Developments
12.8 Cambrex Corporation
12.8.1 Cambrex Corporation Company Information
12.8.2 Cambrex Corporation Business Overview
12.8.3 Cambrex Corporation Revenue in Topical Drugs CDMO Business (2020-2025)
12.8.4 Cambrex Corporation Topical Drugs CDMO Product Portfolio
12.8.5 Cambrex Corporation Recent Developments
12.9 Bora Pharmaceutical CDMO
12.9.1 Bora Pharmaceutical CDMO Company Information
12.9.2 Bora Pharmaceutical CDMO Business Overview
12.9.3 Bora Pharmaceutical CDMO Revenue in Topical Drugs CDMO Business (2020-2025)
12.9.4 Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio
12.9.5 Bora Pharmaceutical CDMO Recent Developments
12.10 Ascendia Pharmaceuticals
12.10.1 Ascendia Pharmaceuticals Company Information
12.10.2 Ascendia Pharmaceuticals Business Overview
12.10.3 Ascendia Pharmaceuticals Revenue in Topical Drugs CDMO Business (2020-2025)
12.10.4 Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio
12.10.5 Ascendia Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.